GSK plc 6-K, filed Jun 1, 2022
GSK plc (GSK)
6-K
2022-06-01
For: 2022-06-01
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on June 1, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of June 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 1 June 2022, London UK - LSE announcement
GSK publishes Prospectus and Circular for proposed demerger of its
Consumer Healthcare business to form Haleon
Further to the announcement made earlier today regarding the
proposed separation of the GSK Consumer Healthcare business from
the GSK Group, GSK confirms that the Circular in relation to the
proposed demerger (the "Demerger") and the Prospectus in relation
to the admission of Haleon plc's ordinary shares to the Premium
listing segment of the Official List of the Financial Conduct
Authority ("FCA") and to trading on the Main Market of the London
Stock Exchange ("LSE") have each been approved by the FCA and
published by GSK and Haleon respectively.
The Circular is available on GSK's website at www.gsk.com/demerger.
The Prospectus is available on Haleon's website
at www.haleon.com. A
copy of the Circular and Prospectus has been submitted to the UK's
National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Demerger is conditional on, among other things, the approval by
GSK shareholders of the Demerger, the GSK Share Consolidation and
the Related Party Transactions at a General Meeting, the receipt of
all necessary mandatory governmental/regulatory approvals and the
final approval of the Demerger by the GSK Board.
The General Meeting will be held at the Sofitel London Heathrow,
Terminal 5, London Heathrow Airport, TW6 2GD on Wednesday 6 July
2022 at 2.30 p.m. (UK time). Shareholders will be able to join and
participate in the General Meeting electronically through the Lumi
website or in person. Further details of how to join the General
Meeting either electronically or in person are set out in the
Circular and the Notice of General Meeting contained within
it.
It is expected that the Demerger will be completed and that the
Haleon ordinary shares will be admitted to the Premium listing
segment of the Official List of the FCA and admitted to trading on
the Main Market of the LSE on
Monday 18 July 2022. Application
will also shortly be made to list American Depositary Shares
("ADSs") representing Haleon ordinary shares on the New York Stock
Exchange ("NYSE")[1].
Description of GSK
GSK is a science-led global healthcare company. For further
information please visit www.gsk.com/about-us.
Disclaimer
GSK makes no representation or warranty as to the appropriateness,
accuracy, completeness or reliability of the information in this
announcement.
This announcement is for information purposes only and is not
intended to and does not constitute or form part of any offer or
invitation to purchase, otherwise acquire, subscribe for, sell,
otherwise dispose of or issue, or any solicitation of any offer to
sell, otherwise dispose of, issue, purchase, otherwise acquire or
subscribe for, any security.
Prior to making any decision in relation to the Demerger,
shareholders should read the Circular and the Prospectus in their
entirety, including the information incorporated by reference.
Shareholders must rely upon their own examination, analysis and
enquiries of GSK and the terms of the Circular and Prospectus,
including the merits and risks involved.
Information regarding forward-looking statements
This announcement contains statements that are, or may be deemed to
be, "forward-looking statements". Forward-looking statements give
GSK's current expectations or forecasts of future events, including
strategic initiatives and future financial condition and
performance relating to Haleon and/or GSK. An investor can identify
these statements by the fact that they do not relate strictly to
historical or current facts. They use words such as 'anticipate',
'estimate', 'expect', 'intend', 'will', 'project', 'plan',
'believe', 'target', 'aim', 'ambition' and other words and terms of
similar meaning in connection with any discussion of future
operating or financial performance. In particular, these include
statements relating to future actions, plans, objectives, goals,
event or intentions. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure Guidance and
Transparency Rules of the Financial Conduct Authority), GSK
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
GSK may make in any documents which it publishes and/or files with
the SEC. All readers, wherever located, should take note of these
disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
Forward-looking statements are subject to assumptions, inherent
risks and uncertainties, many of which relate to factors that are
beyond GSK's control or precise estimate. GSK cautions investors
that a number of important factors, including those in this
document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement.
Such factors include, but are not limited to, those discussed under
Item 3.D 'Risk Factors' in GSK's Annual Report on Form 20-F for
2021, GSK's
Q1 Results for 2022 and
any impacts of the COVID-19 pandemic. Any forward-looking
statements made by or on behalf of GSK speak only as of the date
they are made and are based upon the knowledge and information
available to the directors on the date of this
announcement.
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7823 523562
|
(Consumer)
|
|
|
Emma
White
|
+44 (0)
7823 523562
|
(Consumer)
|
|
|
Rakesh
Patel
|
+44 (0)
7552 484646
|
(Consumer)
|
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1] It
is expected that Haleon ADSs will commence "regular-way" trading on
the NYSE at market open on 22 July 2022. In addition, we expect
that Haleon ADSs will begin trading on a "when-issued" basis on the
NYSE from market open on 18 July 2022 up to and including 21 July
2022.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: June
01, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|